Evaluation of Brain Activity Changes After a Behavior Change Weight Loss Intervention
NCT04522245, Not applicable, Completed, Noom Inc.
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Evaluation of Brain Activity Changes After a Behavior Change Weight Loss Intervention | ClinicalTrials.gov |
| NCT number | NCT04522245 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 70 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Noom Inc. | ClinicalTrials.gov |
| Conditions | Obesity, Behavior, Health, Weight Loss | ClinicalTrials.gov |
| Interventions | Noom Healthy Weight; mobile behavior change program for weight loss., Matched Control | ClinicalTrials.gov |
| First posted | 2020-08-21 | ClinicalTrials.gov |
| Last updated | 2021-07-20 | ClinicalTrials.gov |
Registered outcomes 14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Flanker task performance: Intervention vs control | 16 weeks | Change in amplitude and latency in conflict monitoring stage at 16 weeks | ClinicalTrials.gov |
| Primary | Change in behavioral inhibition | 16 weeks | Change from baseline Flanker task performance at 16 weeks | ClinicalTrials.gov |
| Primary | Change in behavioral inhibition | 16 weeks | Change from baseline n-back task performance at 16 weeks | ClinicalTrials.gov |
| Primary | Change in behavioral inhibition | 16 weeks | Change from baseline Stroop test at 16 weeks | ClinicalTrials.gov |
| Secondary | Change in EEG data: Successful intervention (5% weight loss) in higher engagement subgroup (successful program completers) vs control | 16-week | Task-specific event-related potential (ERP) peak amplitude and latency for channels and * Task-specific event-related potential (ERP) peak amplitude and latency for channels and cortical ROIs * Event-related spectral perturbation (time x frequency power) for channels and cortical ROIs * Mean and relative power spectral density measures for each frequency band + select ratios, for channels and cortical ROIs * Brain connectivity between cortical ROIs | ClinicalTrials.gov |
| Secondary | Comparison of EEG data in program starters to successful program completers | 16-week | * Task-specific event-related potential (ERP) peak amplitude and latency for channels and cortical ROIs * Event-related spectral perturbation (time x frequency power) for channels and cortical ROIs * Mean and relative power spectral density measures for each frequency band + select ratios, for channels and cortical ROIs * Brain connectivity between cortical ROIs | ClinicalTrials.gov |
| Secondary | Within-subject comparison for EEG data | 16-week | * Task-specific event-related potential (ERP) peak amplitude and latency for channels and cortical ROIs * Event-related spectral perturbation (time x frequency power) for channels and cortical ROIs * Mean and relative power spectral density measures for each frequency band + select ratios, for channels and cortical ROIs * Brain connectivity between cortical ROIs | ClinicalTrials.gov |
| Other | Change in Positive and Negative Affect Schedule (PANAS-SF) | 16-week | Explore measure as it relates to change in EEG data | ClinicalTrials.gov |
| Other | Change in quality of life outcome measure scoring (PROMIS-29) | 16-week | Explore measure as it relates to change in EEG data | ClinicalTrials.gov |
| Other | Change in eating behavior measure scoring (Three-Factor Eating Questionnaire) | 16-week | Explore measure as it relates to change in EEG data | ClinicalTrials.gov |
| Other | Change from baseline salivary stress marker at 16 weeks | 16-week | Cortisol | ClinicalTrials.gov |
| Other | Change from baseline salivary tumor necrosis factor alpha at 16 weeks | 16-week | TNF-a | ClinicalTrials.gov |
| Other | Change from baseline salivary interleukin-6 at 16 weeks | 16-week | IL-6 | ClinicalTrials.gov |
| Other | Change from baseline blood pressure (systolic/diastolic) at 16 weeks | 16-week | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Primary outcome | ConductCognition |
| 2-Back Task | Primary outcome | ConductCognition |
| Eriksen Flanker Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)